


AMENDMENTS TO THE CLAIMS

1. - 4. (Cancelled)

5. (Previously Presented) An aryl ureido compound, represented by Formula IIa,



wherein,

R' represents hydrogen or alkyl; and

R¹ represents hydrogen or alkyl; and

R² represents halo; and

R³ and R⁴, independently of each another, represent hydrogen, halo, hydroxy, alkoxy, haloalkyl; or

R³ and R⁴ together form a methylenedioxy ring of the structure -O-CH₂-O-; or

R³ and R⁴ together form a benzo-fused ring, which fused ring is optionally substituted one or more times with substituents selected from halo, hydroxy, alkoxy and haloalkyl.

6. (Original) The aryl ureido derivative of claim 5, which is

2-[3-(3-Bromo-phenyl)-ureido]-4-chloro-5-methyl-benzenesulfonic acid;

4-Chloro-5-methyl-2-[3-(3-trifluoromethyl-phenyl)-ureido]-benzensulphonic acid;

4-Chloro-2-[3-(3-trifluoromethyl-phenyl)-ureido]-benzensulphonic acid;

2-[3-(3-Bromo-phenyl)-ureido]-4-chloro-benzenesulfonic acid; or

4-Chloro-5-methyl-2-(3-naphthalen-2-yl-ureido)-benzensulphonic acid;

or an enantiomer or a mixture of enantiomers, or a pharmaceutically-acceptable addition salt thereof.

7. - 26. (Cancelled)

27. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of a chemical compound of claim 5, or a pharmaceutically-acceptable addition salt thereof, and a pharmaceutically acceptable carrier.

28. (Withdrawn) A method of treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, which disorder, disease or condition is responsive to modulation of an aspartate or a glutamate receptor, which method comprises the step of administering to said animal body in need thereof a therapeutically effective amount of a chemical compound as described in claim 5, or a pharmaceutically-acceptable addition salt thereof.

29. (Withdrawn) The method according to claim 28, which disease, disorder or condition is responsive to modulation of the ionotropic GluR5 receptor.

30. (Withdrawn) The method according to claim 29, wherein the disease, disorder or condition is chronic or acute pain, neuropathic pain, intractable pain, migraine headaches, neurological and psychiatric disorders, depression, anxiety, psychosis, schizophrenia, excitatory amino acid-dependent psychosis, cognitive disorders, dementia, senile dementia, AIDS-induced dementia, stress-related psychiatric disorders, stroke, global and focal ischaemic or haemorrhagic

stroke, cerebral hypoxia/ischaemia, cerebral infarction or cerebral ischaemia resulting from thromboembolic or haemorrhagic stroke, cardiac infarction, brain trauma, brain oedema, cranial/brain trauma, spinal cord trauma, bone-marrow lesions, hypoglycaemia, anoxia, neuronal damage following hypoglycaemia, hypotonia, hypoxia, perinatal hypoxia, cardiac arrest, acute and chronic neurodegenerative diseases or disorders and brain ischaemia of various origin, CNS degenerative disorders, Parkinson's disease, Alzheimer's disease, Huntington's disease, idiopathic and drug induced Parkinson's Disease, amyotrophic lateral sclerosis (ALS), post-acute phase cerebral lesions or chronic diseases of the nervous system, cerebral deficits subsequent to cardiac bypass surgery and grafting, perinatal asphyxia, anoxia from drowning, pulmonary surgery and cerebral trauma, hypoxia-induced nerve cell damage (e.g. in cardiac arrest or bypass operation, or neonatal distress), epilepsy, status epilepticus, seizure disorders, cerebral vasospasm, CNS-mediated spasms, motility disorders, muscular spasms, urinary incontinence, convulsions, disorders responsive to anticonvulsants, autoimmune diseases, emesis, nausea, obesity, chemical dependencies and addictions, addictions and withdrawal symptoms, drug or alcohol induced deficits, drug addiction, ocular damage, retinopathy, retinal neuropathy, tinnitus, tardive dyskinesia.

31. (Withdrawn) The method according to claim 29, wherein the disorder, disease or condition is chronic or acute pain, neuropathic pain, intractable pain, migraine or migraine headaches.

32. (Withdrawn) The method according to claim 29, wherein the disorder, disease or condition is epilepsy, status epilepticus or a seizure disorder.

33. (Cancelled)